国立国際医療研究センター病院におけるニルマトレルビル/リトナビル導入に向けた取り組みと導入後の実態調査-Reference-Cited by-同舟云学术

国立国際医療研究センター病院におけるニルマトレルビル/リトナビル導入に向けた取り組みと導入後の実態調査

Published:2023-07-20 Issue:4 Volume:97 Page:125-135
ISSN:0387-5911
Container-title:Kansenshogaku Zasshi
language:en
Short-container-title:J. J. A. Inf. D

Author:

SHIGENO Ayako¹,OHASHI Yasukata¹,MASUI Ryosuke¹,KIRYU Ayako¹,NAGASHIMA Koji¹,OHASHI Hirotake¹,SETO Keisuke¹,MASUDA Junichi¹,TERUYA Katsuji²,UJIIE Mugen³,OHMAGARI Norio³,NISHIMURA Takahiro¹

Affiliation:

1. Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine

2. AIDS Clinical Center, Center Hospital of the National Center for Global Health and Medicine

3. Disease Control and Prevention Center, Center Hospital of the National Center for Global Health and Medicine

Publisher

The Japanese Association for Infectious Diseases

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/kansenshogakuzasshi/97/4/97_e22043/_pdf

Reference24 articles.

1. 1) Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al.: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386: 1397-408.

2. 2) Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al.: Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023; 76: e342-9.

3. 3) National Institutes of Health: Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. 2022 [cited 2023 Mar 18]; Available from: https://www.covid19treatmentguidelines.nih.gov/

4. 4) The Liverpool Drug Interaction Group: COVID-19 Drug Interactions. UNIVERSITY OF LIVERPOOL [Internet]. 2022 [cited 2023 Mar 18]; Available from: https://www.covid19-druginteractions.org/checker

5. 5) 医療薬学学術第四小委員会: パキロビッド (ニルマトレルビル/リトナビル) の薬物相互作用マネジメントの手引き-第1.1版- [Internet]. 日本医療薬学会. 2022 May [cited 2023 Mar 18] ; Available from: https://www.jsphcs.jp/news/banner/20220228.pdf